We are live on ! Find out more
ADAP

Adaptimmune Therapeutics
ADAP

Delisted

ADAP was delisted on the 27th of October, 2025.

Back to rankings

77 hedge funds and large institutions have $1.28B invested in Adaptimmune Therapeutics in 2020 Q2 according to their latest regulatory filings, with 41 funds opening new positions, 19 increasing their positions, 11 reducing their positions, and 11 closing their positions.

New
Increased
Maintained
Reduced
Closed

403% more capital invested

Capital invested by funds: $255M → $1.28B (+$1.03B)

273% more first-time investments, than exits

New positions opened: 41 | Existing positions closed: 11

73% more repeat investments, than reductions

Existing positions increased: 19 | Existing positions reduced: 11

64% more funds holding

Funds holding: 47 → 77 (+30)

0.74% less ownership

Funds ownership: 14.93% → 14.19% (-0.74%)

49% less call options, than puts

Call options by funds: $5.46M | Put options by funds: $10.7M

Holders
77
Holders Change
+30
Holders Change %
+63.83%
% of All Funds
1.58%
Holding in Top 10
4
Holding in Top 10 Change
+4
Holding in Top 10 Change %
% of All Funds
0.08%
New
41
Increased
19
Reduced
11
Closed
11
Calls
$5.46M
Puts
$10.7M
Net Calls
-$5.22M
Net Calls Change
-$5.3M

Top Buyers

Rank Fund Capital Flow
1
ACA
Avoro Capital Advisors
New York
+$62.8M
2
MCMC
Matrix Capital Management Company
New Hampshire
+$28.5M
3
BBA
Baker Bros. Advisors
New York
+$18.7M
4
RI
RTW Investments
New York
+$16.3M
5
FCM
Farallon Capital Management
California
+$15.7M

Top Sellers

Rank Fund Capital Flow
1
O
OrbiMed
New York
-$6.87M
2
TAM
TFG Asset Management
Cayman Islands
-$2.04M
3
Renaissance Technologies
Renaissance Technologies
New York
-$280K
4
WM
WS Management
Florida
-$131K
5
RJA
Raymond James & Associates
Florida
-$65.3K
Name Holding Trade Value Shares
Change 		Change in
Stake
PA
26
Perceptive Advisors
New York
$4M +$2.51M +400,000 New
Marshall Wace
27
Marshall Wace
United Kingdom
$3.77M +$2.36M +376,340 New
JGC
28
J. Goldman & Co
New York
$3.12M +$1.95M +311,153 New
SCM
29
Suvretta Capital Management
New York
$2.69M +$1.69M +268,900 New
California Public Employees Retirement System
30
California Public Employees Retirement System
California
$2.36M +$1.29M +205,207 +673%
MS
31
Maven Securities
Jersey
$2.25M +$1.41M +225,000 New
AA
32
ALPS Advisors
Colorado
$2.06M +$1.29M +205,448 New
State Street
33
State Street
Massachusetts
$1.72M +$1.08M +172,231 New
PCM
34
Pinz Capital Management
New York
$1.59M +$995K +158,400 New
VIA
35
Vident Investment Advisory
Georgia
$1.41M +$883K +140,529 New
WM
36
WS Management
Florida
$1.22M -$131K -20,831 -15%
Walleye Capital
37
Walleye Capital
New York
$952K +$597K +95,100 New
AC
38
Athanor Capital
New York
$924K +$580K +92,274 New
SFI
39
Susquehanna Fundamental Investments
Pennsylvania
$643K +$403K +64,200 New
Alyeska Investment Group
40
Alyeska Investment Group
Illinois
$626K +$393K +62,567 New
Geode Capital Management
41
Geode Capital Management
Massachusetts
$610K +$60.1K +9,563 +19%
Ensign Peak Advisors
42
Ensign Peak Advisors
Utah
$455K +$285K +45,454 New
LI
43
Leap Investments
Illinois
$402K +$252K +40,200 New
Morgan Stanley
44
Morgan Stanley
New York
$380K +$58.2K +9,272 +32%
Man Group
45
Man Group
United Kingdom
$372K +$20.9K +3,333 +10%
VEA
46
Virtus ETF Advisers
New York
$353K +$221K +35,241 New
Group One Trading
47
Group One Trading
Illinois
$287K +$180K +28,621 New
Commonwealth Equity Services
48
Commonwealth Equity Services
Massachusetts
$285K +$179K +28,500 New
CM
49
Caption Management
Oklahoma
$260K +$163K +26,000 New
AG
50
Aperio Group
California
$234K +$29.7K +4,729 +25%
1
2
3 4

ADAP Hedge Fund Activity: Q2 2020 in Review

77 of the 4,878 institutional investors tracked by Wall St. Rank reported a position in Adaptimmune Therapeutics (ADAP) for Q2 2020, worth a combined $1.28B — up 403% from $255M a quarter earlier.

Buyers outnumbered sellers: 41 funds opened new ADAP positions and 11 closed out — a net gain of 30 holders — while 19 added to existing stakes and 11 trimmed.

The largest buyer was Avoro Capital Advisors, opening a new position worth an estimated $62.8M. The largest seller was OrbiMed, exiting entirely with an estimated $6.87M sold.

  • 77 institutional investors held Adaptimmune Therapeutics (ADAP) as of Q2 2020, up from 47 in Q1 2020.
  • Funds reported $1.28B of Adaptimmune Therapeutics stock for Q2 2020, up 403% quarter-over-quarter.
  • 41 funds opened new Adaptimmune Therapeutics positions in Q2 2020 and 11 closed out, a net change of +30 holders.
  • The largest Adaptimmune Therapeutics buyer in Q2 2020 was Avoro Capital Advisors, an estimated $62.8M added.
  • The largest Adaptimmune Therapeutics seller in Q2 2020 was OrbiMed, an estimated $6.87M sold.

Based on aggregated 13F filings for Q2 2020.